Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Director Stephen Ray Mitchell Sells 5,000 Shares of Stock

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Director Stephen Ray Mitchell sold 5,000 shares of the business’s stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $5.17, for a total value of $25,850.00. Following the completion of the transaction, the director now directly owns 44,857 shares of the company’s stock, valued at approximately $231,910.69. This trade represents a 10.03 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Vanda Pharmaceuticals Trading Down 0.4 %

VNDA opened at $4.98 on Tuesday. The firm’s fifty day moving average price is $4.80 and its two-hundred day moving average price is $5.27. Vanda Pharmaceuticals Inc. has a fifty-two week low of $3.44 and a fifty-two week high of $6.75.

Wall Street Analyst Weigh In

VNDA has been the topic of a number of recent research reports. Cantor Fitzgerald boosted their price objective on Vanda Pharmaceuticals from $11.00 to $13.00 and gave the stock an “overweight” rating in a research note on Thursday, August 1st. HC Wainwright initiated coverage on shares of Vanda Pharmaceuticals in a report on Thursday, October 31st. They issued a “buy” rating and a $18.00 target price on the stock. Finally, StockNews.com initiated coverage on Vanda Pharmaceuticals in a research report on Sunday. They issued a “hold” rating on the stock.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets boosted its position in shares of Vanda Pharmaceuticals by 70.1% in the 1st quarter. BNP Paribas Financial Markets now owns 101,363 shares of the biopharmaceutical company’s stock worth $417,000 after purchasing an additional 41,767 shares during the last quarter. Sei Investments Co. raised its stake in shares of Vanda Pharmaceuticals by 39.6% during the 1st quarter. Sei Investments Co. now owns 518,851 shares of the biopharmaceutical company’s stock worth $2,132,000 after purchasing an additional 147,066 shares in the last quarter. State Board of Administration of Florida Retirement System grew its position in shares of Vanda Pharmaceuticals by 142.4% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 56,002 shares of the biopharmaceutical company’s stock valued at $230,000 after acquiring an additional 32,902 shares during the period. Acadian Asset Management LLC grew its holdings in Vanda Pharmaceuticals by 4.7% during the first quarter. Acadian Asset Management LLC now owns 2,370,335 shares of the biopharmaceutical company’s stock worth $9,740,000 after purchasing an additional 107,203 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of Vanda Pharmaceuticals by 18.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 15,824 shares of the biopharmaceutical company’s stock worth $66,000 after acquiring an additional 2,425 shares during the last quarter. Institutional investors own 88.14% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.